DCLK1 and familial pancreatic carcinoma: As previous studies have shown that targeting DCLK1 with kinase inhibitors resulted in significant reduction of clonogenic potential and invasive capacity in pancreatic cancer and renal cell carcinoma cell lines (31, 33, 34), we next assessed the impact of LRRK2-IN-1 induced DCLK1 inhibition on HNSCC cell lines.